Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has announced its participation in the Centurion One Capital 2nd Annual Bahamas Summit. The event will take place at the Rosewood Baha Mar Hotel in Nassau, Bahamas on October 22-23, 2024.
Michael Redmond, President of Oragenics, is scheduled to deliver a corporate presentation and participate in a Q&A session on October 22, 2024, at 1:20 pm ET. This presentation offers an opportunity for investors and interested parties to gain insights into Oragenics' current projects and future plans in the field of brain health treatments.
Attendees can register for the event through a provided link, allowing them to participate in this significant gathering of industry professionals and potential investors in the pharmaceutical and biotechnology sectors.
Oragenics Inc. (NYSE American: OGEN), un'azienda focalizzata sullo sviluppo di nuovi trattamenti per condizioni di salute legate al cervello, ha annunciato la sua partecipazione al 2° Summit Annuale delle Bahamas di Centurion One Capital. L'evento si svolgerà presso il Rosewood Baha Mar Hotel a Nassau, Bahamas, il 22-23 ottobre 2024.
Michael Redmond, presidente di Oragenics, presenterà una relazione aziendale e parteciperà a una sessione di domande e risposte il 22 ottobre 2024, alle 13:20 ET. Questa presentazione offre un'opportunità per investitori e parti interessate di ottenere informazioni sui progetti attuali e i piani futuri di Oragenics nel campo dei trattamenti per la salute cerebrale.
I partecipanti possono registrarsi per l'evento tramite un link fornito, consentendo loro di partecipare a questo importante incontro di professionisti del settore e potenziali investitori nei settori farmaceutico e biotecnologico.
Oragenics Inc. (NYSE American: OGEN), una empresa centrada en el desarrollo de nuevos tratamientos para condiciones de salud relacionadas con el cerebro, ha anunciado su participación en el 2º Summit Anual de Bahamas de Centurion One Capital. El evento se llevará a cabo en el Rosewood Baha Mar Hotel en Nassau, Bahamas, del 22 al 23 de octubre de 2024.
Michael Redmond, presidente de Oragenics, tiene programada una presentación corporativa y participará en una sesión de preguntas y respuestas el 22 de octubre de 2024, a la 1:20 p. m. ET. Esta presentación ofrece una oportunidad para que los inversores y partes interesadas obtengan información sobre los proyectos actuales y los planes futuros de Oragenics en el campo de los tratamientos para la salud cerebral.
Los asistentes pueden registrarse para el evento a través de un enlace proporcionado, lo que les permite participar en esta importante reunión de profesionales de la industria y posibles inversores en los sectores farmacéutico y biotecnológico.
오라제닉스 Inc. (NYSE American: OGEN)는 뇌 관련 건강 상태를 위한 새로운 치료법 개발에 집중하는 회사로, 센투리온 원 캐피탈 제2회 바하마 정상 회담에 참가한다고 발표했습니다. 이 행사는 로즈우드 바하 마르 호텔에서 2024년 10월 22일-23일에 개최됩니다.
마이클 레드먼드 오라제닉스 사장은 기업 발표를 하고 2024년 10월 22일 오후 1:20 ET에 질의응답 세션에 참여할 예정입니다. 이번 발표는 투자자와 이해관계자에게 오라제닉스의 현재 프로젝트와 향후 계획에 대한 통찰을 제공할 기회를 제공합니다.
참석자는 제공된 링크를 통해 행사에 등록할 수 있으며, 제약 및 생명공학 분야의 업계 전문가와 잠재 투자자들이 모이는 중요한 모임에 참여할 수 있습니다.
Oragenics Inc. (NYSE American: OGEN), une entreprise axée sur le développement de nouvelles traitements pour les conditions de santé liées au cerveau, a annoncé sa participation au 2ème Sommet Annuel des Bahamas de Centurion One Capital. L'événement se tiendra à l'hôtel Rosewood Baha Mar à Nassau, Bahamas, les 22 et 23 octobre 2024.
Michael Redmond, président d'Oragenics, doit faire une présentation d'entreprise et participer à une session de questions-réponses le 22 octobre 2024 à 13h20 ET. Cette présentation offre une opportunité pour les investisseurs et les parties intéressées d'obtenir des informations sur les projets actuels et les futurs plans d'Oragenics dans le domaine des traitements de la santé cérébrale.
Les participants peuvent s'inscrire à l'événement via un lien fourni, leur permettant de prendre part à cette importante réunion de professionnels de l'industrie et d'investisseurs potentiels dans les secteurs pharmaceutique et biotechnologique.
Oragenics Inc. (NYSE American: OGEN), ein Unternehmen, das sich auf die Entwicklung neuer Behandlungen für gehirnbezogene Gesundheitszustände konzentriert, hat seine Teilnahme am 2. Jahrestreffen der Centurion One Capital auf den Bahamas angekündigt. Die Veranstaltung findet im Rosewood Baha Mar Hotel in Nassau, Bahamas, am 22. und 23. Oktober 2024 statt.
Michael Redmond, Präsident von Oragenics, wird am 22. Oktober 2024 um 13:20 Uhr ET eine Unternehmenspräsentation halten und an einer Frage-und-Antwort-Runde teilnehmen. Diese Präsentation bietet Investoren und Interessierten die Möglichkeit, Einblicke in die aktuellen Projekte und zukünftigen Pläne von Oragenics im Bereich der Behandlungen für die Gehirngesundheit zu erhalten.
Teilnehmer können sich über den bereitgestellten Link für die Veranstaltung registrieren, was ihnen die Teilnahme an diesem bedeutenden Treffen von Fachleuten der Branche und potenziellen Investoren im pharmazeutischen und biotechnologischen Bereich ermöglicht.
- None.
- None.
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET.
Details for the presentation are as follows:
Date: Tuesday, October 22, 2024
Time: 1:20 p.m. EDT
Presenter: Michael Redmond, President of Oragenics
Register for the event by clicking here.
About Oragenics:
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Investor Relations:
Rich Cockrell
CG Capital
404-736-3838
ogen@cg.capital
FAQ
When and where is Oragenics (OGEN) presenting at the Centurion One Capital Bahamas Summit?
Who will be representing Oragenics (OGEN) at the Centurion One Capital Bahamas Summit?
What is the focus of Oragenics (OGEN) as mentioned in the press release?
How can interested parties attend Oragenics' (OGEN) presentation at the Centurion One Capital Bahamas Summit?
